A Tariff That Kicks In 2028 Just Crashed Pharma Stocks Today. Here's Why.

$CIPLA was among the top losers on the Nifty this morning after the US announced a 100% tariff on generic drug imports, set to take effect in 2028. Pharma stocks across the board plunged at open, even though this tariff is over two years away from actually applying. This is worth understanding, since it trips people up regularly. Markets don't wait for a policy to actually take effect before pricing it in. The moment a credible, specific policy announcement is made, markets immediately start reassessing future earnings, discounting them back to today. A 100% tariff on generics starting 2028 changes what analysts expect Cipla's US-exposed revenue to look like several years out, and that revised expectation gets priced into the stock today, not in 2028. India is one of the world's largest suppliers of generic drugs to the US, so a tariff at this scale is a genuinely structural risk for the sector, not a minor headline. Companies with heavier US generic exposure will likely see sharper reactions than those more diversified across other markets or specialty drugs. The takeaway. Stock prices reflect expected future cash flows, not just current-quarter numbers. A policy years away from taking effect can move a stock today, because the market's job is pricing in the future, not just reacting to the present.